---
figid: PMC8394439__cancers-13-04054-g001
figtitle: Microbiota-Associated Metabolites and Related Immunoregulation in Colorectal
  Cancer
organisms:
- Escherichia coli
- Helicobacter pylori
- Bacteroides fragilis
- Fusobacterium nucleatum
- Limosilactobacillus reuteri
- Escherichia coli O157H7
- Bifidobacterium longum
- Faecalibacterium prausnitzii
- Streptococcus thermophilus
- Bacteroides thetaiotaomicron
- Anaerobutyricum hallii
- Peptostreptococcus anaerobius
- Bilophila wadsworthia
- Faecalibaculum rodentium
- Streptococcus gallolyticus
- Parabacteroides goldsteinii
- Desulfovibrio sp.
- Camellia sinensis
- Theobroma cacao
- Vaccinium myrtillus
- Ophiocordyceps sinensis
- Rubus occidentalis
- Litsea coreana
- gut metagenome
- metagenome
- human gut metagenome
- metagenomes
- Mus musculus
- Rattus norvegicus
- Homo sapiens
organisms_ner:
- Rattus norvegicus
- Homo sapiens
- Mus musculus
- Drosophila melanogaster
pmcid: PMC8394439
filename: cancers-13-04054-g001.jpg
figlink: /pmc/articles/PMC8394439/figure/cancers-13-04054-f001/
number: F1
caption: SCFAs and their Immunomodulatory Functions. SCFAs, mainly consisting of acetate,
  propionate, and butyrate, act as histone deacetylase (HDAC) inhibitors and ligands
  of G-protein-coupled receptors (GPCRs), leading to the expansion and differentiation
  of FOXP3+ regulatory T (Treg) cells, accompanied by upregulation of immunosuppressive
  IL-10 and transforming growth factor-beta (TGF-β), downregulation of proinflammatory
  cytokines in macrophages and neutrophils, and inhibition of differentiation towards
  T helper type 17 (Th17) cells, thereby suppressing inflammation and carcinogenesis.
  Significantly, SCFAs, especially butyrate, could influence the antitumor responses
  of CD8+ T cells by regulating signaling pathways in dendritic cells (DC), involving
  IL-12, IL-27, and IFN-β, which also have an impact on the combination therapy of
  tumor. Additionally, SCFAs directly inhibited tumors by inhibiting HDAC. Regarding
  their other protective properties, SCFAs could increase the secretion of mucin,
  enhance epithelial integrity by activating inflammasome, and activate the peroxisome
  proliferator-activated receptor-γ (PPAR-γ) pathway, which maintains anaerobic conditions.
  See the text for details. EC, epithelial cell; GC, goblet cell; NF-κB, nuclear factor
  κB; IFN-β, interferon β.
papertitle: Microbiota-Associated Metabolites and Related Immunoregulation in Colorectal
  Cancer.
reftext: Yan Chen, et al. Cancers (Basel). 2021 Aug;13(16):4054.
year: '2021'
doi: 10.3390/cancers13164054
journal_title: Cancers
journal_nlm_ta: Cancers (Basel)
publisher_name: MDPI
keywords: microbiota | metabolites | immunity | inflammation | colorectal cancer
automl_pathway: 0.9463245
figid_alias: PMC8394439__F1
figtype: Figure
redirect_from: /figures/PMC8394439__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8394439__cancers-13-04054-g001.html
  '@type': Dataset
  description: SCFAs and their Immunomodulatory Functions. SCFAs, mainly consisting
    of acetate, propionate, and butyrate, act as histone deacetylase (HDAC) inhibitors
    and ligands of G-protein-coupled receptors (GPCRs), leading to the expansion and
    differentiation of FOXP3+ regulatory T (Treg) cells, accompanied by upregulation
    of immunosuppressive IL-10 and transforming growth factor-beta (TGF-β), downregulation
    of proinflammatory cytokines in macrophages and neutrophils, and inhibition of
    differentiation towards T helper type 17 (Th17) cells, thereby suppressing inflammation
    and carcinogenesis. Significantly, SCFAs, especially butyrate, could influence
    the antitumor responses of CD8+ T cells by regulating signaling pathways in dendritic
    cells (DC), involving IL-12, IL-27, and IFN-β, which also have an impact on the
    combination therapy of tumor. Additionally, SCFAs directly inhibited tumors by
    inhibiting HDAC. Regarding their other protective properties, SCFAs could increase
    the secretion of mucin, enhance epithelial integrity by activating inflammasome,
    and activate the peroxisome proliferator-activated receptor-γ (PPAR-γ) pathway,
    which maintains anaerobic conditions. See the text for details. EC, epithelial
    cell; GC, goblet cell; NF-κB, nuclear factor κB; IFN-β, interferon β.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Il6
  - Il12b
  - H2bc1
  - Gper1
  - Ffar3
  - Ffar2
  - Foxp3
  - Tgfb1
  - Il10
  - Il22
  - Il18
  - Tnf
  - Nfkb1
  - Rela
  - Cd4
  - Slc13a2
  - Gc
  - Lag3
  - Tnfrsf8
  - Il27
  - Nfatc3
  - HDAC9
  - HDAC1
  - HDAC2
  - HDAC3
  - HDAC8
  - HDAC4
  - HDAC5
  - HDAC7
  - HDAC6
  - HDAC10
  - SIRT1
  - SIRT2
  - SIRT3
  - SIRT4
  - SIRT5
  - SIRT6
  - SIRT7
  - HDAC11
  - IL6
  - IL12A
  - IL12B
  - H1-0
  - H1-1
  - H1-2
  - H1-3
  - H1-4
  - H1-5
  - H1-6
  - H1-7
  - H1-8
  - H1-10
  - .na.character
  - H2AB1
  - H2AJ
  - H2AZ2
  - H2AX
  - MACROH2A1
  - MACROH2A2
  - H2AZ1
  - H2AC1
  - H2AC6
  - H2AC7
  - H2AC12
  - H2AC14
  - H2AC21
  - H2AC20
  - H2AC25
  - H2BC1
  - H2BC3
  - H2BC5
  - H2BC9
  - H2BC11
  - H2BC12
  - H2BC13
  - H2BC14
  - H2BC15
  - H2BC17
  - H2BC18
  - H2BC19P
  - H2BC20P
  - H2BC21
  - H2BC26
  - H2BC12L
  - H2BW2
  - H2BW1
  - H3-4
  - H3-5
  - H4C7
  - FFAR3
  - FFAR2
  - FOXP3
  - TGFB1
  - TGFB2
  - TGFB3
  - IL10
  - IL22
  - IL18
  - TNF
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - CD4
  - MUC5AC
  - GC
  - LAG3
  - TNFRSF8
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - CD8A
  - CD8B
  - IL27
  - NFATC3
  - STING1
  - Ltbp1
  - Gusb
  - Pdcd1
  - Ebi3
  - Sting1
  - E(spl)malpha-BFM
  - dpp
  - gbb
  - put
  - mav
  - ec
  - egr
  - Dif
  - dl
  - Rel
  - Me
  - mid
  - Sting
  - aub
  - dc
---
